Postherpetic neuralgia (PHN) is common in the United States. Current treatment options for PHN are fairly limited.
Postherpetic neuralgia is a severe condition of pain arises amidst the nerves. This pain may affect the functioning of the nerves which can be improved by neuromodulation. This study illuminates the various methods of neuromodulation to counter neuralgia pain and suggests that peripheral nerve stimulation improved patients outcomes in postherpetic neuralgia.
Osteoporotic fractures are one of the major causes of increased morbidity and mortality.
The risk of future fractures is further escalated with the previous fractures. This increased risk can be reduced by using anti-osteoporosis medications. In this study, persistence time of different types of anti-osteoporosis drugs have been compared, and it has been concluded that teriparatide and denosumab exhibit better persistence levels than alendronate.
The purpose of this study was to estimate real-world persistence amongst incident users of anti-osteoporosis medications.
Opioids are known to provide significant recovery and relief from pain after surgical operations like surgery of ankle fractures. However, the patients get addictive to opioid use. This study establishes that there exists no association between opioid intake and disability after surgical management of ankle fractures
Opioid-centric pain management strategies have created an epidemic of prescription opioid abuse.
Postherpetic neuralgia causes damage to sensory nerves causing severe neuropathic pain. The study evaluated that early treatment can manage the problem of pain in postherpetic neuralgia. It was a chronic university-based pain clinic study.
As herpes zoster progresses via postherpetic neuralgia (PHN) to well-established PHN, it presents its recalcitrant nature to the treatment.
Endometriosis is a chronic condition that induces dysmenorrhea, pelvic pain and infertility resulting in reduced quality of life in reproductive years of women. This double-blind, randomised study focuses on determining the dose-dependent effect of elagolix and establishes that both higher and lower dose of elagolix is effective in reducing dysmenorrhea pelvic pain in women with endometriosis.
Endometriosis is a chronic, estrogen-dependent condition that causes dysmenorrhea and pelvic pain. Elagolix, an oral, nonpeptide, gonadotropin-releasing hormone (GnRH) antagonist, produced partial to nearly full estrogen suppression in previous studies.
- 1 of 85